In order to further discuss the possible role of SLC6A1 in the CRC progression, we performed KEGG assays with the abnormally expressed genes in CRC specimens with high SLC6A1 expression, and the results revealed that the SLC6A1 expression may be involved in several tumor-related pathways, including PI3K-Akt signaling pathway, relaxin signaling pathway, and TGF-beta signaling pathway. This evidence concerns the gene SLC6A1 and neoplasm.